[Featured Stock] Celltrion Rises on EU Approval Recommendation for Autoimmune Disease Treatment and Phase 3 Clinical Trial Advancement

Celltrion is showing strong performance on positive news such as the European approval recommendation for Stekima, a biosimilar of the autoimmune disease treatment Stelara, and the advancement of Phase 3 clinical trials for Cosentyx, another autoimmune disease treatment.

As of 9:25 AM on the 1st, Celltrion is trading at 177,700 KRW, up 3,400 KRW (1.95%) from the previous close.

On this day, Celltrion announced that on the 27th of last month (local time), the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) issued a positive opinion recommending marketing authorization for Stekima (development code CT-P43), a biosimilar of Stelara for autoimmune diseases, targeting 30 European countries. Stekima received approval recommendations for indications related to autoimmune diseases in Europe, including plaque psoriasis, psoriatic arthritis, and Crohn's disease.

Additionally, on the same day, Celltrion disclosed that on the 28th of last month (local time), it submitted a global Phase 3 clinical trial plan to the U.S. Food and Drug Administration (FDA) for CT-P55, a biosimilar of Cosentyx.